<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="115921">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01800968</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00042633</org_study_id>
    <nct_id>NCT01800968</nct_id>
  </id_info>
  <brief_title>Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)</brief_title>
  <acronym>FIGHT</acronym>
  <official_title>Functional Impact of GLP-1 for Heart Failure Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to test the hypothesis that, compared with placebo, therapy with
      Subcutaneous (SQ) GLP-1 agonist in the post-Acute Heart Failure Syndrome (AHFS) discharge
      period will be associated with greater clinical stability at six months as assessed by a
      composite clinical endpoint.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hospitalization for AHFS identifies individuals at increased risk of death and
      re-hospitalization following discharge. This increased risk justifies intervention with
      novel therapy during the vulnerable post-discharge period to enhance clinical stability and
      prevent early HF mortality and readmissions.

      As heart failure (HF) progresses, impairments in metabolism render the heart substrate
      constrained, limiting cardiac metabolism. Glucagon-like peptide-1 (GLP-1) is a naturally
      occurring incretin peptide that enhances cellular glucose uptake by stimulating insulin
      secretion and insulin sensitivity in target tissues. Preclinical and early-phase clinical
      data support GLP-1 as an effective therapy for advanced HF while use of GLP-1 receptor
      agonists in large numbers of patients with diabetes reveal a good safety profile and
      reductions in adverse cardiac outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Global Ranking of predefined events</measure>
    <time_frame>Randomization to 180 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>All patients participating(regardless of treatment assignment) will be ranked on the basis of a prespecified hierarchical ranking of the following:
Time to death
Time to HF hospitalization
Time-averaged proportional change in Pro-B-type Natriuretic peptide (NT-proBNP) (baseline to 180 days)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Cardiac Structure and function</measure>
    <time_frame>Baseline to 180 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in cardiac structure and function (by echocardiography) from baseline to 180 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Component of the primary endpoint- Time to death</measure>
    <time_frame>Randomization to 30, 90 and 180 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Individual component of the primary endpoint of Death at 30, 90 and 180 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of combined events- Death, HF hospitalization and ED visits</measure>
    <time_frame>Randomization to day 210</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of combined events:
Death and HF hospitalization or
Death + HF hospitalization + Emergency Department (ED) visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in symptoms using the Kansas City Cardiomyopathy Questionnaire (KCCQ)</measure>
    <time_frame>Baseline to day 180</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in KQQC symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Status (6MWT)</measure>
    <time_frame>Baseline, 30, 90 and 180 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Functional status change at 30, 90 and 180 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual component of the primary endpoint- time to HF hospitalization</measure>
    <time_frame>Randomization to 30, 60 and 180 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Individual component of the primary endpoint- time to HF hospitalization from randomization to 30, 60 and 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual component of the primary endpoint- time-averaged proportional change in NT-proBNP</measure>
    <time_frame>Baseline to 180 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Individual component of the primary endpoint- time-averaged proportional change in NT-proBNP from baseline to 180 days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Acute Heart Failure</condition>
  <arm_group>
    <arm_group_label>Liraglutide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Increasing dose from 0.6mg, 1.2mg to 1.8mg SQ daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg SQ daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>Active Drug</description>
    <arm_group_label>Liraglutide</arm_group_label>
    <other_name>Victoza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years

          2. AHFS as defined by the presence of at least 1 symptom (dyspnea, orthopnea, or edema)
             AND 1 sign (rales on auscultation, peripheral edema, ascites, pulmonary vascular
             congestion on chest radiography)

          3. AHFS is the primary cause of hospitalization

          4. Prior clinical diagnosis of HF

          5. Left Ventricular Ejection Fraction(LVEF) ≤ 40%  during the preceding 3 months (if no
             echo within the preceding 3 months, an LVEF ≤ 30% during the preceding three years is
             acceptable)

          6. On evidence-based medication for HF (including beta-blocker and ACE-inhibitor/ARB) or
             previously deemed intolerant

          7. Use of at least 80 mg or furosemide total daily dose (or equivalent) prior to
             admission for AHFS (a lower dose of a loop diuretic combined with a thiazide will
             count as an &quot;equivalent&quot;)

          8. Willingness to provide informed consent

        Exclusion Criteria:

          1. AHFS due to acute myocarditis or acute Myocardial Infarction

          2. Ongoing hemodynamically significant arrhythmias contributing to HF decompensation

          3. Inotrope, intra-aortic balloon pump (IABP) or other mechanical circulatory support
             use at the time of consent. Prior use will not exclude a patient.

          4. Current or planned left ventricular assist device therapy in next 180 days

          5. United Network for Organ Sharing status 1A or 1B

          6. B-type natriuretic peptide(BNP)&lt; 250 or NT-proBNP&lt;1,000 (Not required per protocol
             but if available and too low would be an exclusion; within 48 hours of consent)

          7. Hemoglobin (Hgb) &lt; 8.0 g/dl

          8. Glomerular filtration rate(GFR) &lt; 20 ml/min/1.73 m2 within 48 hours of consent

          9. Systolic blood pressure &lt; 80 mmHg at consent

         10. Resting Heart Rate &gt; 110 at consent

         11. Acute coronary syndrome within 4 weeks as defined by electrocardiographic (ECG)
             changes and biomarkers of myocardial necrosis (e.g. troponin) in an appropriate
             clinical setting (chest discomfort or anginal equivalent)

         12. Percutaneous Coronary Intervention, coronary artery bypass grafting or new
             biventricular pacing within past 4 weeks

         13. Primary hypertrophic cardiomyopathy

         14. Infiltrative cardiomyopathy

         15. Constrictive pericarditis or tamponade

         16. Complex congenital heart disease

         17. Non-cardiac pulmonary edema

         18. More than moderate aortic or mitral stenosis

         19. Intrinsic (prolapse, rheumatic) valve disease with severe mitral, aortic or tricuspid
             regurgitation

         20. Sepsis, active infection (excluding cystitis) or other comorbidity driving the HF
             decompensation

         21. Acute or chronic severe liver disease as evidenced by any of the following:
             encephalopathy, variceal bleeding, International Normalized Ration (INR) &gt; 1.7 in the
             absence of anticoagulation treatment

         22. Terminal illness (other than HF) with expected survival of less than 1 year

         23. Previous adverse reaction to the study drug

         24. Receipt of any investigational product in the previous 30 days.

         25. Enrollment or planned enrollment in another randomized therapeutic clinical trial in
             next 6 months.

         26. Inability to comply with planned study procedures

         27. Pregnancy or breastfeeding mothers

         28. Women of reproductive age not on adequate contraception

         29. History of acute or chronic pancreatitis

         30. History of symptomatic gastroparesis

         31. Familial or personal history of medullary thyroid cancer or multiple endocrine
             neoplasia type-2 (MEN2)

         32. Prior weight-loss surgery (i.e., Roux-en-Y gastric bypass) or other gastric surgery
             associated with increased endogenous GLP-1 production

         33. Prior or ongoing treatment with GLP-1 receptor agonists

         34. Ongoing treatment with dipeptidyl peptide-IV inhibitors (1 week washout required)

         35. Ongoing treatment with thiazolidinedione

         36. Oxygen-dependent chronic obstructive pulmonary disease

         37. Diabetic patients with history of 2 or more severe hypoglycemia, Diabetic
             Ketoacidosis(DKA) or hyperglycemic, hyperosmotic nonketotic coma in the preceding 12
             months.

         38. Anticipated discharge from hospital to a supported care facility

         39. Diagnosis of Type 1 Diabetes Mellitus

         40. If diabetic, inadequate glycemic control with glucose level &gt; 300 mg/dL within 24
             hours of randomization
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Hernandez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eugene Bruanwald, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Harvard University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gayle E Paynter, MBA, PMP</last_name>
    <phone>919-668-8641</phone>
    <email>gayle.e.paynter@duke.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Christiana Care Health Services</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mitchell Saltzberg, MD</last_name>
      <phone>302-733-1200</phone>
      <email>msaltzberg@christianacare.org</email>
    </contact>
    <investigator>
      <last_name>Mitchell Saltzberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javed Butler, MD</last_name>
      <phone>404-778-5273</phone>
      <email>javed.butler@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Javed Butler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stuart Russell, MD</last_name>
      <phone>410-955-5708</phone>
      <email>srusse14@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Stuart Russell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Givertz, MD</last_name>
      <phone>617-732-7367</phone>
      <email>mgivertz@partners.org</email>
    </contact>
    <investigator>
      <last_name>Michael Givertz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Semigran, MD</last_name>
      <phone>617-726-8862</phone>
      <email>msemigran@partners.org</email>
    </contact>
    <investigator>
      <last_name>Marc Semigran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Kiernan, MD</last_name>
      <phone>617-636-4155</phone>
      <email>mkiernan@tuftsmedicalcenter.org</email>
    </contact>
    <investigator>
      <last_name>Michael Kiernan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston VA Healtcare System</name>
      <address>
        <city>West Roxbury</city>
        <state>Massachusetts</state>
        <zip>02132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neal Lakdawala, MD</last_name>
      <phone>617-525-9574</phone>
      <email>nlakdawala@partners.org</email>
    </contact>
    <investigator>
      <last_name>Neal Lakdawala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Redfield, MD</last_name>
      <phone>507-284-1281</phone>
      <email>redfield.margaret@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Margaret Redfield, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Ewald, MD</last_name>
      <phone>314-454-7009</phone>
      <email>gewald@dom.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Gregory Ewald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Louis University Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Hauptman, MD</last_name>
      <phone>314-268-5293</phone>
      <email>hauptmpj@slu.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Hauptman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mike Felker, MD</last_name>
      <phone>919-668-8919</phone>
      <email>michael.felker@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Felker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Durham VA Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Donahue, MD</last_name>
      <phone>919-286-0411</phone>
      <email>mark.donahue@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Donahue, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southeast Regional Medical Center</name>
      <address>
        <city>Lumberton</city>
        <state>North Carolina</state>
        <zip>28538</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melvin Echols, MD</last_name>
      <phone>910-386-1252</phone>
      <email>melvin.echols@dm.duke.edu</email>
    </contact>
    <investigator>
      <last_name>Melvin Echols, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clevelan Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wilson Tang, MD</last_name>
      <phone>216-444-2121</phone>
      <email>tangw@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Wilson Tang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals- Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guilherme Oliveria, MD</last_name>
      <phone>216-444-4036</phone>
      <email>guilherme.oliveira@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Guilherme Oliveris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metro Health System</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Dunlap, MD</last_name>
      <phone>216-778-2711</phone>
      <email>mdunlap@metrohealth.org</email>
    </contact>
    <investigator>
      <last_name>Mark Dunlap, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lancaster Heart and Stroke Foundation</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tareck Nossuli, MD</last_name>
      <email>tnossuli2@lghealth.org</email>
    </contact>
    <investigator>
      <last_name>Tareck Nossuli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvaina</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Margulies, MD</last_name>
      <phone>215-707-2006</phone>
      <email>ken.margulies@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Kenneth Margulies, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jefferson Medical College</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Mather, MD</last_name>
      <phone>215-955-2050</phone>
      <email>paul.mather@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Mather, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rene Alvarez, MD</last_name>
      <phone>215-707-1924</phone>
      <email>rene.alvarez@tuhs.temple.edu</email>
    </contact>
    <investigator>
      <last_name>Rene Alvarez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michael Debakey VA Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Deswal, MD</last_name>
      <phone>713-794-7441</phone>
      <email>adeswal@bcm.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Anita Deswal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Abdallah Kfoury, MD</last_name>
      <phone>801-507-4789</phone>
      <email>akfoury@imail.org</email>
    </contact>
    <investigator>
      <last_name>Abdallah Kfoury, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah School of Medicine</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josef Stehlik, MD</last_name>
      <phone>801-585-1686</phone>
      <email>josef.stehlik@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Josef Stehlik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Utah VA Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josef Stehlik, MD</last_name>
      <phone>801-585-1686</phone>
      <email>josef.stehlik@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Josef Stehlik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Vermont- Fletcher Allen Health Care</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin LeWinter, MD</last_name>
      <phone>802-847-2879</phone>
      <email>martin.lewinter@vtmednet.org</email>
    </contact>
    <investigator>
      <last_name>Martin LeWinter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Haissam Haddad, MD</last_name>
      <phone>1-613-761-5165</phone>
      <email>hhaddad@ottawaheart.ca</email>
    </contact>
    <investigator>
      <last_name>Haissam Haddad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Rouleau, MD</last_name>
      <email>jean.rouleau@umontreal.ca</email>
    </contact>
    <investigator>
      <last_name>Jean Rouleau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 16, 2013</lastchanged_date>
  <firstreceived_date>February 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
